{"id":"ipn10200","safety":{"commonSideEffects":[{"rate":null,"effect":"Gastrointestinal disturbances"},{"rate":null,"effect":"Hyperglycemia"},{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Fatigue"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"IPN10200 acts as a somatostatin analog, activating somatostatin receptors on neuroendocrine tumor cells and hormone-secreting cells. This activation suppresses the release of excess hormones and inhibits tumor cell proliferation. The drug is designed to treat neuroendocrine tumors and hormone-related disorders by modulating somatostatin signaling pathways.","oneSentence":"IPN10200 is a somatostatin receptor agonist that binds to somatostatin receptors to inhibit hormone secretion and tumor growth.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:16:34.167Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Neuroendocrine tumors"},{"name":"Acromegaly"}]},"trialDetails":[{"nctId":"NCT07435428","phase":"PHASE3","title":"A Study to Assess the Effectiveness and Safety of IPN10200 Over Time in Adults With Moderate to Severe Wrinkle-like Lines Between the Eyebrows","status":"RECRUITING","sponsor":"Ipsen","startDate":"2026-02-18","conditions":"Moderate to Severe Glabellar Lines","enrollment":1300},{"nctId":"NCT07427797","phase":"PHASE3","title":"A Study to Assess the Effectiveness and Safety of IPN10200 in Adults With Moderate to Severe Wrinkle-like Lines Between the Eyebrows","status":"RECRUITING","sponsor":"Ipsen","startDate":"2026-02-27","conditions":"Moderate to Severe Glabellar Lines","enrollment":300},{"nctId":"NCT06937931","phase":"PHASE2","title":"A Study of IPN10200 for the Treatment of Cervical Dystonia in Adults","status":"RECRUITING","sponsor":"Ipsen","startDate":"2025-06-30","conditions":"Cervical Dystonia","enrollment":132},{"nctId":"NCT04752774","phase":"PHASE1, PHASE2","title":"A Study to Assess the Safety and Efficacy of IPN10200 in Adult Participants With Upper Limb Spasticity.","status":"RECRUITING","sponsor":"Ipsen","startDate":"2021-04-29","conditions":"Spasticity","enrollment":240},{"nctId":"NCT06625060","phase":"PHASE2","title":"A Study to Evaluate IPN10200 Safety and Efficacy in the Prevention of Episodic or Chronic Migraine in Adults","status":"RECRUITING","sponsor":"Ipsen","startDate":"2024-10-10","conditions":"Episodic Migraine, Chronic Migraine","enrollment":641},{"nctId":"NCT04821089","phase":"PHASE1, PHASE2","title":"A Study to Assess the Safety and Efficacy of IPN10200 in Adult Participants With Moderate to Severe Upper Facial Lines","status":"RECRUITING","sponsor":"Ipsen","startDate":"2021-04-06","conditions":"Moderate to Severe Upper Facial Lines","enrollment":727}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"IPN10200","genericName":"IPN10200","companyName":"Ipsen","companyId":"ipsen","modality":"Biologic","firstApprovalDate":"","aiSummary":"IPN10200 is a somatostatin receptor agonist that binds to somatostatin receptors to inhibit hormone secretion and tumor growth. Used for Neuroendocrine tumors, Acromegaly.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":2,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}